Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study
- 1Washington University in St. Louis
Abstract
BackgroundCancer incidence and mortality are rising in Africa, yet the distribution and determinants of cancer in high HIV-prevalence regions remain limited. We characterized cancer epidemiology, treatment, and survival among adults in western Kenya, where HIV prevalence ranges between 10.3% and 11.7%.
MethodsThis retrospective cohort study included adults ([≥]18 years) with cancer treated at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kisumu, Kenya, between Jan 1, 2014, and Dec 31, 2024, followed through June 30, 2025. Data were abstracted from paper records into REDCap. Negative binomial models estimated annual trends, Kaplan-Meier curves evaluated survival, and Cox proportional hazards models evaluated mortality
FindingsAmong 3978 patients (64% female; median age 53.9 years, IQR (42.0, 65.1), annual case counts rose from 29 to 708, averaging a 38% annual increase (95% CI 29-48). Cervical (24%), esophageal (13.6%), breast (12%), prostate (8%), and colorectal (4%) cancers accounted for 62% of cases. 1305 (33%) of cancer patients were living with HIV and 802 (20%) had unknown HIV status. Among patients whose cancer was assigned a stage, 72% presented at stage III-IV. 1973 (50%) received cancer-directed treatment, and 51% had an unscheduled clinic visit lapse of at least 180 days. Cancer-directed treatment was the strongest protective factor for mortality (adjusted hazard ratio [aHR] 0{middle dot}27, 95% CI 0{middle dot}22-0{middle dot}32); HIV-positive status (aHR 1{middle dot}43, 1{middle dot}19-1{middle dot}71), HIV-unknown status (aHR 1{middle dot}48, 1{middle dot}20-1{middle dot}81), and poor or missing performance status were independently associated with higher mortality, robust across sensitivity analyses.
InterpretationCancer mortality was strongly associated with treatment and HIV status at diagnosis. Closing the treatment-access gap and adopting routine opt-out HIV testing at the first oncology visit are essential for integrated cancer care in high-HIV-prevalence settings.
FundingResearch reported in this publication was supported by the American Cancer Society; the Washington University in St. Louis Institute of Clinical and Translational Sciences through a grant from the National Center for Advancing Translational Sciences (NCATs) of the National Institutes of Health; Just-in-Time funding, and the National Cancer Institute Center Support Grant P30CA091842.
Related
- Association between primary-site surgery and overall survival in non-metastatic and metastatic colorectal cancer: a population-based study using the Surveillance, Epidemiology, and End Results database
- Epidemiology, exposure patterns and survival of malignant mesothelioma in Apulia, Italy (1993–2025): a population-based retrospective registry study
- Epidemiology of malaria and district-level factors associated with malaria elimination in Sumatra region, Indonesia: a retrospective analysis of surveillance data
- Prognostic factors and conditional survival analysis in primary thyroid lymphoma: a retrospective cohort study using the Surveillance, Epidemiology, and End Results database.
- Changing epidemiology and survival of HPV-associated oropharyngeal cancer in Denmark: four decades of population-based data
BibTeX
@misc{mangale2026cancer,
title = {{Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study}},
author = {D. Mangale and H. Adhiambo and P. Adagi and D. Atieno and B. Bowe and C. Wafula and A. McLigeyo and T. A. Odeny},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.28.26364183},
url = {https://www.medrxiv.org/content/10.64898/2026.09.28.26364183v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study
AU - D. Mangale
AU - H. Adhiambo
AU - P. Adagi
AU - D. Atieno
AU - B. Bowe
AU - C. Wafula
AU - A. McLigeyo
AU - T. A. Odeny
PY - 2026
DA - 2026/09/28
PB - medRxiv
DO - 10.64898/2026.09.28.26364183
UR - https://www.medrxiv.org/content/10.64898/2026.09.28.26364183v1
AB - BackgroundCancer incidence and mortality are rising in Africa, yet the distribution and determinants of cancer in high HIV-prevalence regions remain limited. We characterized cancer epidemiology, treatment, and survival among adults in western Kenya, where HIV prevalence ranges between 10.3% and 11.7%. MethodsThis retrospective cohort study included adults ([≥]18 years) with cancer treated at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) in Kisumu, Kenya, between Jan 1, 2014, and Dec 31, 2024, followed through June 30, 2025. Data were abstracted from paper records into REDCap. Negative binomial models estimated annual trends, Kaplan-Meier curves evaluated survival, and Cox proportional hazards models evaluated mortality FindingsAmong 3978 patients (64% female; median age 53.9 years, IQR (42.0, 65.1), annual case counts rose from 29 to 708, averaging a 38% annual increase (95% CI 29-48). Cervical (24%), esophageal (13.6%), breast (12%), prostate (8%), and colorectal (4%) cancers accounted for 62% of cases. 1305 (33%) of cancer patients were living with HIV and 802 (20%) had unknown HIV status. Among patients whose cancer was assigned a stage, 72% presented at stage III-IV. 1973 (50%) received cancer-directed treatment, and 51% had an unscheduled clinic visit lapse of at least 180 days. Cancer-directed treatment was the strongest protective factor for mortality (adjusted hazard ratio [aHR] 0{middle dot}27, 95% CI 0{middle dot}22-0{middle dot}32); HIV-positive status (aHR 1{middle dot}43, 1{middle dot}19-1{middle dot}71), HIV-unknown status (aHR 1{middle dot}48, 1{middle dot}20-1{middle dot}81), and poor or missing performance status were independently associated with higher mortality, robust across sensitivity analyses. InterpretationCancer mortality was strongly associated with treatment and HIV status at diagnosis. Closing the treatment-access gap and adopting routine opt-out HIV testing at the first oncology visit are essential for integrated cancer care in high-HIV-prevalence settings. FundingResearch reported in this publication was supported by the American Cancer Society; the Washington University in St. Louis Institute of Clinical and Translational Sciences through a grant from the National Center for Advancing Translational Sciences (NCATs) of the National Institutes of Health; Just-in-Time funding, and the National Cancer Institute Center Support Grant P30CA091842.
ER -